Boardroom Alpha
Boardroom Alpha
DARE · Additional Proxy Materials (DEFA14A) · Filed June 1, 2026

Dare Bioscience Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
June 1, 2026
Ticker
DARE
Accession
0001493152-26-026545
Boardroom Alpha · Filing insights

Daré Bioscience releases definitive additional materials detailing a social-media voting reminder campaign ahead of the June 11, 2026 annual meeting.

About Dare Bioscience Inc
Market cap
$32M
1Y TSR
−13.3%
3Y TSR
−39.9%
Board grade
C+
Sector
Healthcare
CEO
Sabrina Martucci Johnson
Last annual meeting: Jun 11, 2026 · View full Dare Bioscience Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
       
Check the appropriate box:  
       
  Preliminary Proxy Statement  
     
  Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))
     
  Definitive Proxy Statement  
     
  Definitive Additional Materials  
     
  Soliciting Material under § 240.14a-12

 

DARÉ BIOSCIENCE, INC.

 

(Name of Registrant as Specified In Its Charter)

 

 

 

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

  No fee required
  Fee paid previously with preliminary materials
  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 
 

 

Daré Bioscience, Inc. may post one or more of the following messages on various social media platforms, including LinkedIn, Facebook, X, Instagram and TikTok, from time to time beginning on June 1, 2026:

 

Post 1

 

Your vote takes less time than this post will take to read.

 

Daré Bioscience’s (Nasdaq: DARE) 2026 Annual Meeting of Stockholders is June 11. If you own shares, you can vote right now — it can take under five minutes.

 

Vote online at proxyvote.com using the control number on your proxy card or Notice of Internet Availability.

 

One thing that catches people: if your shares are held through a broker, bank or similar organization, that organization will not automatically vote your shares on all matters being submitted for a vote. If you want your shares to be voted on all matters, you have to give voting instructions to that organization, and the deadline for receiving your instructions is likely earlier than June 11.

 

The Notice for the Annual Meeting and the related Proxy Statement and Form 10-K are all at proxyvote.com. Meeting is virtual: virtualshareholdermeeting.com/DARE2026

 

#DaréBioscience #DARE #WomensHealth #AnnualMeeting #ShareholderVote

 

Post 2

 

Four days left to vote.

 

Daré Bioscience’s (Nasdaq: DARE) Annual Meeting of Stockholders is June 11. If you haven’t voted your shares yet, now’s the time.

 

Vote in minutes at proxyvote.com, or by phone at 1-800-690-6903. Your control number is on your proxy card or Notice of Internet Availability.

 

Holding shares through a broker, bank or similar organization? If you want your shares to be voted on all matters being submitted for a vote, you’ll need to give voting instructions to that organization — and check their deadline for receiving your instructions, which is likely before June 11.

 

Every vote counts. Thank you for being part of Daré Bioscience.

 

The Notice for the Annual Meeting and the related Proxy Statement and Form 10-K are all at proxyvote.com. Meeting is virtual: virtualshareholdermeeting.com/DARE2026

 

#DaréBioscience #DARE #WomensHealth #AnnualMeeting

 

 
 

 

Post 3

 

Your 30-second reminder if you own Daré Bioscience stock

 

Our 2026 Annual Meeting of Stockholders is June 11. Voting can take under five minutes — head to proxyvote.com and use the control number on your proxy card or Notice of Internet Availability.

 

One thing that trips people up: if you hold shares through a broker, bank or similar organization, you have to give voting instructions to that organization to have your shares voted on all matters being submitted for a vote, and their deadline for receiving your instructions is likely before June 11.

 

Link in bio. Daré Bioscience (Nasdaq: DARE).

 

The Notice for the Annual Meeting and the related Proxy Statement and Form 10-K are all at proxyvote.com. Meeting is virtual: virtualshareholdermeeting.com/DARE2026

 

#DaréBioscience #DARE #WomensHealth #AnnualMeeting #ShareholderVote

 

Post 4

 

Four days left to vote your Daré shares.

 

The Daré Bioscience (Nasdaq: DARE) Annual Meeting of Stockholders is June 11. If you haven’t voted yet, it takes minutes — proxyvote.com or call 1-800-690-6903. Your control number is on your proxy card or Notice of Internet Availability.

 

Holding your shares through a broker, bank or similar organization? Give your voting instructions to them, and check their deadline for receiving your instructions — it is likely earlier than June 11.

 

Every vote counts. Link in bio.

 

The Notice for the Annual Meeting and the related Proxy Statement and Form 10-K are all at proxyvote.com. Meeting is virtual: virtualshareholdermeeting.com/DARE2026

 

#DaréBioscience #DARE #WomensHealth #AnnualMeeting

 

 

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Dare Bioscience Inc (DARE)

Reference

Frequently asked questions

When did Dare Bioscience Inc file this DEFA14A?
Dare Bioscience Inc (DARE) filed this Additional Proxy Materials (DEFA14A) with the SEC on June 1, 2026. The accession number assigned by EDGAR is 0001493152-26-026545.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Daré Bioscience releases definitive additional materials detailing a social-media voting reminder campaign ahead of the June 11, 2026 annual meeting. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Dare Bioscience Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Dare Bioscience Inc has filed under CIK 1401914, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer